State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 201–300 of 1,003
Pharmacokinetics of Antibacterial Agents in the CSF of Children and Adolescents
Sullins, A. K., & Abdel‐Rahman, S. M. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0017-5 · Cited by 152
Bulitta, J. B., Yang, J. C., Yohonn, L., Ly, N. S., Brown, S. V., D'Hondt, R. E., Jusko, W. J., Forrest, A., & Tsuji, B. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00881-09 · Cited by 152
“Identification of the pharmacokinetic/pharmacodynamic (PKPD) index that best predicts a successful outcome became a cornerstone of optimization of antimicrobial therapy (2, 16, 21).”
BackgroundNew, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice
Bustamante, J. M., Craft, J. M., Crowe, B., Ketchie, S. A., & Tarleton, R. L. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit420 · Cited by 152
“functioning through a maximum concentration mechanism have extended postantibiotic effects—impacting pathogen growth after complete removal of the compound [34].”
BackgroundA guide to therapeutic drug monitoring of β‐lactam antibiotics
Fratoni, A. J., Nicolau, D. P., & Kuti, J. L. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2505 · Cited by 153
Gunderson, B. W., Ibrahim, K. H., Hovde, L. B., Fromm, T. L., Reed, M. D., & Rotschafer, J. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.905-909.2003 · Cited by 152
“In addition, larger doses of drug are thought to maximize the activity of concentrationdependent antibiotics (6).”
BackgroundAbdulla, A., Dijkstra, A., Hunfeld, N., Endeman, H., Bahmany, S., Ewoldt, T. M. J., Muller, A. E., van Gelder, T., Gommers, D. A. M. P. J., & Koch, B. C. P. (2020) · Critical Care · doi:10.1186/s13054-020-03272-z · Cited by 151
Montero, A., Ariza, J., Corbella, X., Domenech, A., Cabellos, C., Ayats, J., Tubau, F., Ardanuy, C., & Gudiol, F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1946-1952.2002 · Cited by 151
“Finally, based on previous studies (8), single doses”
BackgroundMethodContinuous infusion of β-lactam antibiotics in severe infections: a review of its role
Roberts, J. A., Paratz, J., Paratz, E., Krueger, W. A., & Lipman, J. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.02.002 · Cited by 150
Ertapenem: A Review of its Use in the Treatment of Bacterial Infections
Keating, G. M., & Perry, C. M. (2005) · Drugs · doi:10.2165/00003495-200565150-00013 · Cited by 149
In Vitro Antibacterial Activity and Pharmacodynamics of New Quinolones
Dalhoff, A., & Schmitz, F. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0907-5 · Cited by 148
Suboptimal Aminoglycoside Dosing in Critically Ill Patients
Rea, R. S., Capitano, B., Bies, R. R., Bigos, K. L., Smith, R. B., & Lee, H. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31818b6b2f · Cited by 145
Dagan, R., Leibovitz, E., Fliss, D. M., Leiberman, A., Jacobs, M. R., Craig, W., & Yagupsky, P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.43-50.2000 · Cited by 134
“On the basis of pharmacodynamic modeling, Craig (10) and Craig and Andes (11) have suggested that serum b-lactam concentrations need to exceed the MIC for 40 to 50% of the dosing interval to provide high rates of bacteriologic cure.”
BackgroundInfluentialSelf-citationAndes, D. R., & Craig, W. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1376-1383.2006 · Cited by 142
Self-citationClinical Relevance of Macrolide-Resistant Streptococcus pneumoniae for Community-Acquired Pneumonia
Lynch, J. P., & Martínez, F. J. (2002) · Clinical Infectious Diseases · doi:10.1086/324527 · Cited by 142
“Studies have shown that clinical outcomes correlate better with PK/PD parameters than with MIC values [209].”
BackgroundOhmori, T., Suzuki, A., Niwa, T., Ushikoshi, H., Shirai, K., Yoshida, S., Ogura, S., & Itoh, Y. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.03.001 · Cited by 141
Management of severe community-acquired pneumonia of children in developing and developed countries
Principi, N., & Esposito, S. (2010) · Thorax · doi:10.1136/thx.2010.142604 · Cited by 141
Antifungal serum concentration monitoring: an update
Goodwin, M. L., & Drew, R. H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm389 · Cited by 141
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140
“These investigations have been useful for optimizing dosing regimens and for defining clinical resistance or guiding the development of susceptibility breakpoints (1, 7, 12, 16, 18, 43, 44, 47).”
BackgroundBriscoe, S., McWhinney, B. C., Lipman, J., Roberts, J. A., & Ungerer, J. P. J. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.09.016 · Cited by 140
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial Infections
Nuermberger, E. L., & Grosset, J. H. E. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1109-5 · Cited by 140
“studies using a suitable model are directly applicable to human infections [36].”
BackgroundMethodInfluentialHow predictive is PK/PD for antibacterial agents?
Frimodt‐Møller, N. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00029-8 · Cited by 139
Olofsson, S. K. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl135 · Cited by 124
Craig, W. A., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01590-12 · Cited by 138
“aeruginosa and Enterobacteriaceae (12).”
Self-citationMuller, A. E., Huttner, B. D., & Huttner, A. (2018) · Drugs · doi:10.1007/s40265-018-0880-z · Cited by 138
“We know from preclinical studies that for the cephalosporins, for example, the minimum value of fT[MIC for bacteriostasis is 40% for Enterobacteriaceae, while 60–65% is needed for near-maximal bacterial kill [33, 36, 37].”
BackgroundResultBetrosian, A. P., Frantzeskaki, F., Xanthaki, A., & Georgiadis, G. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600951184 · Cited by 129
“The t /MIC is the most predictive pharmacokinetic/ pharmacodynamic parameter of the in vivo efficacy of b-lactams in animal models [19].”
BackgroundPharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent
Meagher, A. K., Ambrose, P. G., Grasela, T. H., & Ellis‐Grosse, E. J. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.05.006 · Cited by 138
“If, however, the antimicrobial agent in question has a moderate to prolonged postantibiotic effect (PAE), time of exposure is less important and the AUC/MIC ratio is the important determinant of efficacy (Craig, 1998).”
BackgroundTarget site penetration of fosfomycin in critically ill patients
Joukhadar, C., Klein, N., Dittrich, P., Zeitlinger, M., Geppert, A., Skhirtladze, K., Frossard, M., Heinz, G., & Müller, M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg187 · Cited by 138
Groll, A. H., Mickiene, D., Petraitiene, R., Petraitis, V., Lyman, C. A., Bacher, J. S., Piscitelli, S. C., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2845-2855.2001 · Cited by 138
“Linking pharmacokinetic and pharmacodynamic information provides critical information for interspecies scaling, definition of breakpoints for in vitro susceptibility testing, and the selection of appropriate dosing regimens (4).”
BackgroundSaravolatz, L. D., Pea, F., & Viale, P. (2006) · Clinical Infectious Diseases · doi:10.1086/504383 · Cited by 137
“Although t 1 MIC should be 50%–60% of the dosing interval for standard efficacy [14], it should increase to 100% in immunocompromised patients, efficacy improving only slightly with concentrations 4–5-fold the MIC [15].”
Livermore, D. M., Carter, M. W., Bagel, S., Wiedemann, B., Baquero, F., Loza, E., Endtz, H. P., van den Braak, N., Fernandes, C. J., Fernandes, L. A., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1860-1867.2001 · Cited by 137
“The choice of breakpoints partially reflects the fact that carbapenems require levels above the MICs for only 15 to 40% of the dosage interval for therapeutic efficacy, whereas cephalosporins and penicillins require levels above the MICs for at least 40% of the dosage intervals (4).”
BackgroundDiagnosis of infection in sepsis: An evidence-based review
Cohen, J., Brun‐Buisson, C., Torres, A., & Jorgensen, J. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000145917.89975.f5 · Cited by 136
Falsey, A. R., Formica, M. A., Treanor, J. J., & Walsh, E. E. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.9.4160-4165.2003 · Cited by 131
Pharmacodynamic Principles of Antimicrobial Therapy in the Prevention of Resistance
Burgess, D. S. (1999) · CHEST Journal · doi:10.1378/chest.115.suppl_1.19s · Cited by 136
Antibiotic-induced population fluctuations and stochastic clearance of bacteria
Coates, J. L., Park, B. R., Dai, L., Şimşek, E., Chaudhry, W. N., & Kim, M. (2018) · eLife · doi:10.7554/elife.32976 · Cited by 136
“…the ‘minimum inhibitory concentration’ (MIC; the lowest concentration of the drug that inhibits population growth) as the most critical parameter for characterizing the dynamics of a bacterial population under antibiotics (Regoes et al., 2004; Czock et al., 2009; Craig, 1998; Falagas et al., 2012).”
BackgroundPharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria
Hegde, S. S., Reyes, N., Wiens, T., Vanasse, N., Skinner, R., McCullough, J. L., Kaniga, K., Pace, J., Thomas, R., Shaw, J., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.3043-3050.2004 · Cited by 135
Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., & Bohrmueller, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00478-08 · Cited by 134
“These investigations have been useful for optimizing treatment regimens, defining clinical resistance, and guiding the development of susceptibility breakpoints (1, 3, 7, 8, 14, 16, 43, 45).”
BackgroundAntifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa
Crandon, J. L., Bulik, C. C., Kuti, J. L., & Nicolau, D. P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01183-09 · Cited by 121
“Numerous in vivo animal studies with various cephalosporins have suggested that an fT MIC target of 50 to 70% is required to achieve maximal reductions in the numbers of CFU of Gram-negative bacteria (5).”
BackgroundMechanism-based pharmacokinetic–pharmacodynamic modeling of antimicrobial drug effects
Czock, D., & Keller, F. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9069-x · Cited by 134
“The factor 4 was arbitrarily chosen based on visual inspection of kill curve data [51,52].”
MethodPreclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
Ong, V., Hough, G., Schlosser, M., Bartizal, K., Balkovec, J. M., James, K. D., & Krishnan, B. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-16 · Cited by 126
“Although animal models of aspergillosis, such as the one used here and in similar studies (24), remain useful for drug evaluation and prediction of antimicrobial effect in humans (25, 26), the work toward improving future aspergillosis models (27, 28) and the challenges inherent in translational research in general ar…”
BackgroundAhmad, Z., PANDEY, R., Sharma, S., & Khuller, G. K. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.12.009 · Cited by 133
“In addition, it is the basis of intermittent tuberculosis therapy [17].”
BackgroundRationale for Combination Antifungal Therapy
Lewis, R. E., & Kontoyiannis, D. P. (2001) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.149s.34505 · Cited by 117
“One way to address this problem would be to assay drug concentrations in homogenized kidney tissue, a controversial practice since there is no consensus regarding what these drug levels actually represent: interstitial concentrations, intracellular concentrations, or both.(77) Even if survival or mycologic efficacy is…”
BackgroundBacterial Meningitis in Children: Critical Review of Current Concepts
Yogev, R., & Guzman‐Cottrill, J. A. (2005) · Drugs · doi:10.2165/00003495-200565080-00005 · Cited by 131
“quinolones, where increasing CSF concentrations The recommendations for antibacterial therapy resulted in higher rates of bacterial killing which for pneumococcal meningitis are based on current in allows for less frequent dose administration.[30] vitro susceptibility patterns (table I).”
BackgroundNegri, M.-C., Lipsitch, M., Blázquez, J., Levin, B. R., & Baquero, F. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2485-2491.2000 · Cited by 131
“Indeed, pharmacodynamics of beta-lactam drugs shows that the antibacterial activity of these compounds is proportional to the time at concentrations above the MIC or to the area under the concentration-time curve above the MIC (7).”
BackgroundInfluentialCiprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria
Fantin, B., Duval, X., Massias, L., Alavoine, L., Chau, F., Retout, S., Andremont, A., & Mentré, F. (2009) · The Journal of Infectious Diseases · doi:10.1086/600122 · Cited by 130
Antibiotic therapy as personalized medicine – general considerations and complicating factors
Moser, C. E., Lerche, C. J., Thomsen, K., Hartvig, T., Schierbeck, J., Jensen, P. Ø., Ciofu, O., & Høiby, N. (2019) · Apmis · doi:10.1111/apm.12951 · Cited by 130
“Subsequent studies, however, showed that the serum concentrations had to be >MIC in the entire dosing interval in 76 critically ill patients (22,23).”
BackgroundAndes, D. R., & Craig, W. A. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01265.x · Cited by 130
“Studies with b-lactams against organisms with widely varying MICs have demonstrated that successful treatment outcome is associated with dosing regimens in which drug levels remain above the MIC for approximately one-half of the dosing interval or there is a percentage time above MIC of 50% (%T > MIC) [11,25].”
BackgroundMethodResultInfluentialSelf-citationContinuous infusion versus intermittent administration of meropenem in critically ill patients
Thalhammer, F., Traunmuller, F., El Menyawi, I., Frass, M., Hollenstein, U. M., Locker, G. J., Stoiser, B., Staudinger, T., Thalhammer-Scherrer, R., & Burgmann, H. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.4.523 · Cited by 125
Breilh, D., Texier-Maugein, J., Allaouchiche, B., Saux, M., & Boselli, E. (2013) · Journal of Chemotherapy · doi:10.1179/1973947812y.0000000032 · Cited by 130
Rhodes, N. J., Liu, J., O’Donnell, J. N., Dulhunty, J. M., Abdul-Aziz, M. H., Berko, P. Y., Nadler, B., Lipman, J., & Roberts, J. A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002836 · Cited by 130
“ciated with efficacy for beta-lactams (6, 7).”
Streptococcus pneumoniae: Epidemiology and patterns of resistance
Jacobs, M. R. (2004) · The American Journal of Medicine Supplements · doi:10.1016/j.amjmed.2004.07.003 · Cited by 129
Bulitta, J. B., Duffull, S. B., Kinzig‐Schippers, M., Holzgrabe, U., Stephan, U., Drusano, G. L., & Sörgel, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01477-06 · Cited by 129
“For beta-lactams, the duration of the nonprotein-bound concentration above the MIC (fT MIC) best predicts the drugrelated response (12, 17).”
BackgroundSlama, T. G., Amin, A. J., Brunton, S., File, T. M., Milkovich, G., Rodvold, K. A., Sahm, D. F., Varón, J., & Weiland, D. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.007 · Cited by 130
Muller, A. E., Punt, N., & Mouton, J. W. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks468 · Cited by 120
Doern, G. V. (2001) · Clinical Infectious Diseases · doi:10.1086/321847 · Cited by 129
“n p 1531 b These values are based on studies conducted in normal healthy volunteers and do not take into account protein binding [44].”
BackgroundPharmacokinetics and Pharmacodynamics of Fluoroquinolones
Rodvold, K. A., & Neuhauser, M. M. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.16.233s.33992 · Cited by 128
“Our understanding of clinical pharmacodynamics of antiinfective agents dramatically increased during the past decade.(100) Application of this knowledge should allow clinicians to establish optimum antibiotic dosages in an attempt to maximize efficacy, minimize toxicity, and limit development of resistance.”
BackgroundScaglione, F., & Paraboni, L. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.03.015 · Cited by 128
Frimodt‐Møller, N. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00105-x · Cited by 127
Biphasic release of gentamicin from chitosan/fucoidan nanoparticles for pulmonary delivery
Huang, Y., Li, R., Chen, J.-Y., & Chen, J. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.11.072 · Cited by 127
“Previous studies have discussed antimicrobial efficacy by using he combination of PK and PD parameters and have proposed that he AUC/MIC ratio as a remarkable PK/PD parameter for indicating he antimicrobial efficacy of aminoglycosides (Craig, 1998).”
BackgroundBrown, J. E., Brown, K., & Forrest, A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05609-11 · Cited by 126
“This is because hVISA and agr mutant testing is not routinely performed in most clinical laboratories due to workload and feasibility issues (7).”
BackgroundCapitano, B., Mattoes, H. M., Shore, E. T., O’Brien, A., Braman, S. S., Sutherland, C., & Nicolau, D. P. (2004) · CHEST Journal · doi:10.1378/chest.125.3.965 · Cited by 126
Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians
Nix, D. E., Majumdar, A. K., & DiNubile, M. J. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh205 · Cited by 126
What Do We Really Know About Antibiotic Pharmacodynamics?
Gunderson, B. W., Ross, G. H., Ibrahim, K. H., & Rotschafer, J. C. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.18.302s.33905 · Cited by 124
“Another important consideration in pharmacodynamics is the presence or absence of a PAE, which refers to the ability to suppress bacterial growth after a scripted exposure to an antibiotic.(88) In general, b-lactams produce a PAE only against gram-positive organisms, although some authors suggest the class, especially…”
BackgroundResultInfluentialPletz, M. W. R., Rau, M., Bulitta, J., De Roux, A., Burkhardt, O., Kruse, G., Kurowski, M., Nord, C. E., & Lode, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3765-3772.2004 · Cited by 113
“By taking into account the fact that a T MIC of 30 to 40% is required for ertapenem and that a T MIC of 60 to 70% is required for ceftriaxone and the fact that both antibiotics exhibit free fractions between 5 and 10% in the therapeutic concentration range (6, 10), the directly measured concentration of ertapenem at 1…”
BackgroundInfluentialUlldemolins, M., Roberts, J. A., Wallis, S. C., Rello, J., & Lipman, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq184 · Cited by 117
Suzuki, Y., Kawasaki, K., Sato, Y., Tokimatsu, I., Itoh, H., Hiramatsu, K., Takeyama, M., & Kadota, J. (2012) · Chemotherapy · doi:10.1159/000343162 · Cited by 124
Ahmadzia, H. K., Patel, E. M., Joshi, D., Liao, C., Witter, F. R., Heine, R. P., & Coleman, J. S. (2015) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001064 · Cited by 124
“Because cefazolin is a concentration-independent antibiotic, the length of time above minimum inhibitory concentration, and not peak concentration, best describes its bactericidal activity, which might explain these results.(13) There was a decrease in endometritis over the study time period.”
BackgroundAndes, D., Ambrose, P. G., Hammel, J. P., Van Wart, S. A., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 119
“Anti-infective pharmacodynamic (PD) investigation is a critical tool for development of optimal dosing strategies and for establishment of definitions of clinically relevant drug resistance (2, 14).”
BackgroundPharmacokinetics and Pharmacodynamics of Antifungals
Andes, D. R. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.007 · Cited by 124
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem
Mattoes, H. M., Kuti, J. L., Drusano, G. L., & Nicolau, D. P. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)80001-8 · Cited by 124
Cerf, O., Carpentier, B., & Sandérs, P. (2009) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2009.10.002 · Cited by 123
Antimicrobial regional limb perfusion in horses
Rubio‐Martínez, L. M., & Cruz, A. M. (2006) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.228.5.706 · Cited by 123
Meagher, A. K., Passarell, J. A., Cirincione, B. B., Wart, S. A. V., Liolios, K., Babinchak, T., Ellis‐Grosse, E. J., & Ambrose, P. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01084-06 · Cited by 123
“In vivo PK-PD infection models have long been used to study the activity of antimicrobial agents and to identify PK-PD targets and thresholds (3, 11).”
BackgroundUdy, A. A., Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C. D., Shirwadkar, C., Eastwood, G. M., Myburgh, J., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.022 · Cited by 123
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments
Rex, J. H., Eisenstein, B. I., Alder, J. D., Goldberger, M. J., Meyer, R., Dane, A. L., Friedland, I. R., Knirsch, C. A., Sanhai, W. R., Tomayko, J. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70293-1 · Cited by 123
Bradley, J. S., Dudley, M. N., & Drusano, G. L. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000094940.81959.14 · Cited by 122
“Other antibiotics that do not kill the pathogen any more quickly with higher concentrations may just need to be exposed to the organism for a certain time period to achieve the same result.(15) For these antibiotics the T MIC may be the best predictor of clinical success.”
BackgroundPharmacodynamics of doxycycline
Cunha, B. A., Domenico, P., & Cunha, C. B. (2000) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2000.00058-2.x · Cited by 122
PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTIBIOTICS IN MENINGITIS
Andes, D. R., & Craig, W. A. (1999) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70096-9 · Cited by 122
Self-citationSiegel, R. E. (2008) · Respiratory Care · doi:10.4187/respcare.08530471 · Cited by 122
Pharmacokinetic profile that reduces nephrotoxicity of gentamicin in a perfused kidney-on-a-chip
Kim, S., LesherPerez, S. C., Kim, B. C. C., Yamanishi, C., Labuz, J. M., Leung, B., & Takayama, S. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/015021 · Cited by 115
Dosage Adjustments for Antibacterials in Obese Patients: Applying Clinical Pharmacokinetics
Bearden, D. T., & Rodvold, K. A. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038050-00003 · Cited by 121
Pharmacodynamics: Relation to Antimicrobial Resistance
Rybak, M. J. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.04.001 · Cited by 120
Vassallo, A., Silletti, M. F., Faraone, I., & Milella, L. (2020) · Journal of Nanomaterials · doi:10.1155/2020/6905631 · Cited by 120
“The study of the pharmacokinetics-pharmacodynamics of antibiotics and of the so-called pharmacokinetic/pharmacodynamic indices (PK/PD indices) [23] is a rather hot topic as wrong therapeutic regimens not only do not allow us to achieve the desired clinical result but it also promotes the development of resistance, bec…”
BackgroundPlasma and Tissue Depletion of Florfenicol and Florfenicol-amine in Chickens
Anadón, A., Martínez, M., Martínez, M., Ríos, A. D., Caballero, V., Arés, I., & Martínez-Larrañaga, M. R. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf802138y · Cited by 120
Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents
Zhao, M., Lepak, A. J., & Andes, D. R. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.008 · Cited by 119
“pneumonia, skin and soft tissue infection, intra-abdominal infections and septicemia).(1,63) The model is also attractive as use of two thighs per animal (two”
BackgroundToutain, P., Pelligand, L., Lees, P., Bousquet‐mélou, A., Ferran, A. A., & Turnidge, J. D. (2020) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12917 · Cited by 119
Pasipanodya, J. G., & Gumbo, T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00749-10 · Cited by 118
“A second important development is antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science, founded on the work of Eagle and Craig (5, 21, 22, 39).”
BackgroundIn Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin
Andes, D. R., & Craig, W. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01264-06 · Cited by 118
Self-citationLodise, T. P., Lomaestro, B., Rodvold, K. A., Danziger, L. H., & Drusano, G. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4718-4724.2004 · Cited by 116
“Similar to other beta-lactam antibiotics, piperacillin-tazobactam exhibits time-dependent killing and the T MIC appears to be the best outcome predictor (7, 8).”
BackgroundResultMen, P., Li, H.-B., Zhai, S.-D., & Zhao, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146224 · Cited by 118
Rodríguez-Hernández, M. J., Pachón, J., Pichardo, C., Cuberos, L., Ibáñez-Martínez, J., García-Curiel, A., Caballero, F. J., Moreno, I., & Me, J.-M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.4.493 · Cited by 117
Andes, D., Safdar, N., Marchillo, K., & Conklin, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.674-684.2006 · Cited by 116
“The use of pharmacodynamic analyses to correlate antimicrobial pharmacokinetics with treatment outcome has been critical for adequate comparison of the in vivo potencies of antimicrobials (2, 3, 11).”
BackgroundMurthy, B., & Schmitt‐Hoffmann, A. H. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00003 · Cited by 116
Basarab, G. S., Kern, G. H., McNulty, J. M., Mueller, J. P., Lawrence, K. R., Vishwanathan, K., Alm, R. A., Barvian, K. K., Doig, P., Galullo, V., et al. (2015) · Scientific Reports · doi:10.1038/srep11827 · Cited by 116
A Nosocomial Outbreak of Fluoroquinolone‐ResistantStreptococcus pneumoniae
Weiss, K., Restieri, C., Gauthier, R., Laverdière, M., McGeer, A., Davidson, R., Kilburn, L., Bast, D. J., de Azavedo, J., & Low, D. E. (2001) · Clinical Infectious Diseases · doi:10.1086/322658 · Cited by 116
“However, pharmacokinetic/pharmacodynamic data based on administration of 15 mg/kg of cefuroxime twice a day suggest that pneumococcal MICs of 4 mg/mL may be required before clinical failure occurs [32].”
BackgroundWhat has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 98
Barco, S., Mesini, A., Barbagallo, L., Maffia, A., Tripodi, G., Pea, F., Saffioti, C., Castagnola, E., & Cangemi, G. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113273 · Cited by 115
Miller, B. W., Hershberger, E., Benziger, D. P., Trinh, M. M., & Friedland, I. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06349-11 · Cited by 115
“The PK/pharmacodynamic index that best correlates with the therapeutic efficacy of cephalosporins is the time above the MIC of the infecting pathogen (T MIC), the longer half-life of ceftolozane compared to that of some other cephalosporins is potentially advantageous (2).”
BackgroundContinuous beta-lactam infusion in critically ill patients: the clinical evidence
Abdul-Aziz, M. H., Dulhunty, J. M., Bellomo, R., Lipman, J., & Roberts, J. A. (2012) · Annals of Intensive Care · doi:10.1186/2110-5820-2-37 · Cited by 108
“Based on numerous in vitro and in vivo experimental data, it is the duration of effective antibiotic exposure that is more important for these timedependent antibiotics [14-17].”
BackgroundSchintler, M., Traunmüller, F., Metzler, J., Kreuzwirt, G., Spendel, S., Mauric, O., Popovic, M., SCHARNAGL, E., & Joukhadar, C. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp230 · Cited by 115
“MIC)] is the predominant PK–pharmacodynamic (PD) parameter showing a high predictive value of antimicrobial killing.(25,29) According to experiments performed by Craig,(29) it may be inferred that effective bacterial killing for ‘time-dependent’ antibiotics such as fosfomycin may be expected when the MIC for the patho…”
Background
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.